Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ARTL
ARTL logo

ARTL Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Artelo Biosciences Inc (ARTL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.540
1 Day change
-5.22%
52 Week Range
85.800
Analysis Updated At
2026/05/08
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

ARTL is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock is oversold and near support, but the broader trend is still bearish, fundamentals remain weak, there is no recent news catalyst, and proprietary signals do not show a buy setup. Best decision: hold and wait for clear trend improvement before buying.

Technical Analysis

ARTL is in a weak downtrend. The MACD histogram is negative, the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and price is below the pivot at 3.407 and near S1 support at 2.799. RSI_6 at 10.243 indicates the stock is extremely oversold, which can support a short-term bounce, but it does not override the bearish trend. The pattern-based outlook suggests only a modest next-day rebound and a weak next-week trend, so the technical setup is not strong enough for an immediate long-term entry.

Positive Catalysts

  • ["RSI is extremely oversold, which could support a short-term rebound.", "Post-market change was positive at 2.26%, suggesting some late-session recovery interest.", "Pattern-based data shows a 19.42% chance of strength over the next month."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no current event-driven catalyst.", "No AI Stock Picker signal today.", "No recent SwingMax signal.", "Hedge funds are neutral and insiders are neutral, with no meaningful accumulation trend.", "Financials remain weak: revenue is still 0, net income is negative at -4.166M, and EPS deteriorated sharply year over year.", "Bearish moving averages and negative MACD confirm the downtrend.", "Price is trading below the pivot and closer to support than resistance, indicating weak trend structure."]

Financial Performance

In 2025/Q4, ARTL showed no revenue growth because revenue remained at 0. Net income was -4.166 million, improving 10.27% year over year but still deeply negative. EPS dropped to -6.18, down 70.44% YoY, which shows earnings weakness persists. Overall, the latest quarter does not support a long-term buy case.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible Wall Street upgrade/downgrade trend to support the stock. Based on the available data, the pro side is limited to oversold technicals, while the con side is stronger due to weak financials, no news catalyst, and no bullish proprietary signal.

Wall Street analysts forecast ARTL stock price to rise
Analyst Rating
0
Wall Street analysts forecast ARTL stock price to rise
Buy
Hold
Sell
0
Current: 2.680
sliders
Low
0
Averages
0
High
0
0
Current: 2.680
sliders
Low
0
Averages
0
High
0
D. Boral Capital
Jason Kolbert
Buy
to
Hold
downgrade
AI Analysis
2025-09-08
Reason
D. Boral Capital
Jason Kolbert
Price Target
AI Analysis
2025-09-08
downgrade
Buy
to
Hold
Reason
D. Boral Capital analyst Jason Kolbert downgraded Artelo Biosciences to Hold from Buy and removed the firm's prior price target following the company's "unexpected" $3M capital raise last week that came after what appeared to be an unsuccessful crypto-related strategy. Repeated attempts to reach management for clarification have been unsuccessful, notes the analyst, who cites the combination of "poor communication, a confusing strategic direction, and a dilutive capital raise" for the firm's more cautious stance.
D. Boral Capital
Hold
to
Buy
upgrade
$20
2025-07-08
Reason
D. Boral Capital
Price Target
$20
2025-07-08
upgrade
Hold
to
Buy
Reason
D. Boral Capital upgraded Artelo Biosciences (ARTL) to Buy from Hold with a $20 price target. The firm, which has adjusted its model and raised assumptions for the now completed reverse split, continues to view Artelo as an emerging biotechnology company focused on Cachexia and Chemotherapy-induced peripheral neuropathy with the lead program ART27.13, a Phase 2 asset acquired from Astra-Zenca (AZN), the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ARTL
Unlock Now

People Also Watch